Tower Research Capital (TRC)’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $179K | Buy |
2,802
+2,548
| +1,003% | +$132K | ﹤0.01% | 1778 |
|
|
2026
Q1 | $12.2K | Sell |
254
-125
| -33% | -$5.54K | ﹤0.01% | 3803 |
|
|
2025
Q4 | $15.6K | Buy |
379
+325
| +602% | +$13K | ﹤0.01% | 3283 |
|
|
2025
Q3 | $2.1K | Sell |
54
-25,221
| -100% | -$819K | ﹤0.01% | 4683 |
|
|
2025
Q2 | $699K | Buy |
25,275
+23,733
| +1,539% | +$604K | 0.02% | 730 |
|
|
2025
Q1 | $34.2K | Sell |
1,542
-6,941
| -82% | -$143K | ﹤0.01% | 2516 |
|
|
2024
Q4 | $168K | Buy |
8,483
+4,575
| +117% | +$104K | ﹤0.01% | 1835 |
|
|
2024
Q3 | $97.7K | Buy |
+3,908
| New | +$95.2K | ﹤0.01% | 2252 |
|
|
2024
Q2 | – | Sell |
-758
| Closed | -$15K | – | 5863 |
|
|
2024
Q1 | $15K | Sell |
758
-9,534
| -93% | -$186K | ﹤0.01% | 3273 |
|
|
2023
Q4 | $181K | Buy |
10,292
+9,008
| +702% | +$148K | ﹤0.01% | 2186 |
|
|
2023
Q3 | $22.3K | Sell |
1,284
-918
| -42% | -$15.5K | ﹤0.01% | 3276 |
|
|
2023
Q2 | $31K | Sell |
2,202
-2,713
| -55% | -$36.3K | ﹤0.01% | 2993 |
|
|
2023
Q1 | $53K | Buy |
4,915
+4,001
| +438% | +$52.7K | ﹤0.01% | 2437 |
|
|
2022
Q4 | $13K | Sell |
914
-2,163
| -70% | -$31.5K | ﹤0.01% | 3616 |
|
|
2022
Q3 | $39K | Sell |
3,077
-1,203
| -28% | -$13.7K | ﹤0.01% | 3378 |
|
|
2022
Q2 | $42K | Buy |
4,280
+1,755
| +70% | +$16.4K | ﹤0.01% | 3056 |
|
|
2022
Q1 | $25K | Sell |
2,525
-5,459
| -68% | -$57.8K | ﹤0.01% | 3325 |
|
|
2021
Q4 | $94K | Buy |
7,984
+3,510
| +78% | +$43.1K | ﹤0.01% | 2268 |
|
|
2021
Q3 | $50K | Sell |
4,474
-1,027
| -19% | -$13.4K | ﹤0.01% | 2963 |
|
|
2021
Q2 | $77K | Buy |
5,501
+4,167
| +312% | +$63.3K | ﹤0.01% | 2642 |
|
|
2021
Q1 | $25K | Sell |
1,334
-1,416
| -51% | -$29K | ﹤0.01% | 3707 |
|
|
2020
Q4 | $49K | Sell |
2,750
-16,671
| -86% | -$293K | ﹤0.01% | 3143 |
|
|
2020
Q3 | $298K | Buy |
19,421
+16,733
| +623% | +$314K | ﹤0.01% | 2196 |
|
|
2020
Q2 | $68K | Buy |
2,688
+1,254
| +87% | +$26.2K | ﹤0.01% | 2798 |
|
|
2020
Q1 | $22K | Sell |
1,434
-5,380
| -79% | -$84.2K | ﹤0.01% | 1668 |
|
|
2019
Q4 | $76K | Buy |
6,814
+6,784
| +22,613% | +$58.9K | 0.01% | 1104 |
|
|
2019
Q3 | $0 | Buy |
+30
| New | +$331 | ﹤0.01% | 4317 |
|
|
2019
Q2 | – | Sell |
-498
| Closed | -$9K | – | 3988 |
|
|
2019
Q1 | $9K | Buy |
+498
| New | +$9.62K | ﹤0.01% | 2736 |
|
|
2018
Q4 | – | Sell |
-1,199
| Closed | -$31K | – | 4105 |
|
|
2018
Q3 | $31K | Buy |
1,199
+969
| +421% | +$18.8K | ﹤0.01% | 2053 |
|
|
2018
Q2 | $4K | Buy |
+230
| New | +$4.16K | ﹤0.01% | 3139 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Tower Research Capital (TRC)'s KNSA Position: Q2 2026 in Review
Tower Research Capital (TRC) increased its Kiniksa Pharmaceuticals (KNSA) stake by 1,003% in Q2 2026, buying an estimated $132K and bringing the position to 2,802 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #1778.
Tower Research Capital (TRC) first reported a position in KNSA in Q2 2018 and has held it in 30 quarters since. The position peaked at $699K in Q2 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Tower Research Capital (TRC) held 2,802 shares of Kiniksa Pharmaceuticals worth $179K as of Q2 2026.
- Tower Research Capital (TRC) bought 2,548 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $132K.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1778 holding.
- Tower Research Capital (TRC) first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- Tower Research Capital (TRC)'s Kiniksa Pharmaceuticals position peaked at $699K in Q2 2025.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.